Mohawk Restasis deal could backfire on all pharma patent holders, not just Allergan
Last week saw a further backlash against Allergan’s 2017 Saint Regis Mohawk deal, with the introduction of proposed legislation to eliminate sovereign immunity as grounds for exemption from cancellation hearings before the US Patent and Trademark…
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.